PAVmed Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that PAVmed Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $3.00M | Mar 24, 2025 |
| FY2023 | Dec 31, 2023 | $2.50M | Mar 25, 2024 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $71.0K | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $3.00M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $2.45M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $377.0K | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $500.0K | Mar 14, 2023 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | ($85.0K) | Apr 6, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $401.0K | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $39.79M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($64.18M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | ($88.98M) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | ($50.35M) | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | ($34.28M) | Apr 6, 2022 |
| FY2020 | Dec 31, 2019 | ($16.46M) | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | ($17.97M) | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | ($9.52M) | Apr 1, 2019 |
| FY2016 | Dec 31, 2016 | ($1.71M) | Feb 16, 2017 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($21.81M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($44.49M) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($68.80M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | ($91.09M) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | ($54.39M) | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | ($23.35M) | Apr 6, 2022 |
| FY2020 | Dec 31, 2019 | ($14.30M) | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | ($10.56M) | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | ($8.03M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($5.65M) | Mar 14, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.49M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $5.93M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $14.28M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $25.34M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $19.85M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $10.96M | Apr 6, 2022 |
| FY2020 | Dec 31, 2019 | $6.63M | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | $4.25M | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | $2.62M | Apr 1, 2019 |
| FY2016 | Dec 31, 2016 | $607.0K | Feb 16, 2017 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($5.21M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($33.55M) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($52.04M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | ($70.99M) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | ($40.59M) | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | ($21.91M) | Apr 6, 2022 |
| FY2020 | Dec 31, 2019 | ($13.36M) | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | ($8.79M) | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | ($6.61M) | Apr 1, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $31.0K | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $55.0K | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $242.0K | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $1.54M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $1.47M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $55.0K | Apr 6, 2022 |
| FY2020 | Dec 31, 2019 | $27.0K | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | $26.6K | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | $5.3K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $21.8K | Mar 14, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $38.81M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $30.66M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $33.12M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $53.98M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $86.98M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $19.78M | Apr 6, 2022 |
| FY2020 | Dec 31, 2019 | $7.24M | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | $8.50M | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | $1.64M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $870.4K | Mar 14, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.51M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $37.69M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $57.14M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $43.05M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $7.56M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $20.25M | Apr 6, 2022 |
| FY2020 | Dec 31, 2019 | $11.88M | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | $10.97M | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | $4.49M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $1.19M | Mar 14, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $33.97M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($2.50M) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($53.83M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | ($9.68M) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $61.67M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $1.90M | Apr 6, 2022 |
| FY2020 | Dec 31, 2019 | ($3.82M) | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | ($2.31M) | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | ($2.85M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($319.1K) | Mar 14, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($258.73M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($254.97M) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($294.43M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | ($228.17M) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | ($138.91M) | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | ($88.28M) | Apr 6, 2022 |
| FY2020 | Dec 31, 2019 | ($53.72M) | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | ($36.99M) | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | ($17.91M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($7.70M) | Mar 14, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.54M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $1.19M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $19.64M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $39.74M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $77.26M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $17.26M | Apr 6, 2022 |
| FY2020 | Dec 31, 2019 | $6.22M | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | $8.22M | Apr 14, 2020 |
| FY2018 | Dec 31, 2017 | $1.54M | Apr 1, 2019 |
| FY2018 | Dec 31, 2016 | $585.7K | Apr 1, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (5) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | 99 | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | (9) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | (15) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 14, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (5) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | 14 | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | (9) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | (15) | Mar 25, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 927,934 | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | 373,300 | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | 8.58M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | 6.30M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | 86.37M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | 63.82M | Apr 6, 2022 |
| FY2020 | Dec 31, 2019 | 40.48M | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | 27.14M | Apr 14, 2020 |
| FY2019 | Dec 31, 2017 | 14.55M | Apr 14, 2020 |
| FY2017 | Dec 31, 2016 | 13.33M | Mar 14, 2018 |